or Try an Advanced Search...

    Technical Analysis for ZLAB - Zai Lab Limited

    Grade Last Price % Change Price Change
    C 20.03 0.35% 0.07
    ZLAB closed up 0.55 percent on Monday, September 9, 2024, on 75 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical ZLAB trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.35%
    Spinning Top Other 0.35%
    Multiple of Ten Bearish Other 0.35%
    Wide Bands Range Expansion 0.35%
    Overbought Stochastic Strength 0.35%
    New Uptrend Bullish 0.91%
    180 Bullish Setup Bullish Swing Setup 0.91%
    Wide Bands Range Expansion 0.91%
    Overbought Stochastic Strength 0.91%
    200 DMA Resistance Bearish 1.99%
    Older End-of-Day Signals for ZLAB ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 3 hours ago
    Rose Above Previous Day's High about 6 hours ago
    200 DMA Resistance about 6 hours ago
    Up 2% about 6 hours ago
    Up 1% about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ZLAB Chart by TradingView
    Basic chart:

    Profile

    Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases

    Is ZLAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Aug 29 Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
    Aug 22 Zai Lab Announces Participation in September Investor Conferences
    Aug 17 Zai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past year
    Aug 7 Zai Lab Limited (ZLAB) Q2 2024 Earnings Call Transcript
    Aug 6 Zai Lab ADR of -$0.82 misses by $0.12, revenue of $100.5M beats by $7.36M
    Aug 6 Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
    Jul 17 China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
    Jul 16 Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    Jul 15 Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
    Jul 10 Best Momentum Stocks to Buy for July 10th
    See more ZLAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 31.22
    52 Week Low 13.48
    Average Volume 510,863
    200-Day Moving Average 20.14
    50-Day Moving Average 18.11
    20-Day Moving Average 18.25
    10-Day Moving Average 19.53
    Average True Range 0.90
    RSI (14) 64.03
    ADX 26.62
    +DI 28.40
    -DI 10.80
    Chandelier Exit (Long, 3 ATRs) 17.80
    Chandelier Exit (Short, 3 ATRs) 18.70
    Upper Bollinger Bands 20.99
    Lower Bollinger Band 15.50
    Percent B (%b) 0.81
    BandWidth 30.08
    MACD Line 0.58
    MACD Signal Line 0.36
    MACD Histogram 0.2147
    Fundamentals Value
    Market Cap 1.97 Billion
    Num Shares 98.7 Million
    EPS -3.10
    Price-to-Earnings (P/E) Ratio -6.44
    Price-to-Sales 7.25
    Price-to-Book 2.09
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 21.18
    Resistance 3 (R3) 21.13 20.67 20.97
    Resistance 2 (R2) 20.67 20.36 20.70 20.90
    Resistance 1 (R1) 20.32 20.17 20.50 20.37 20.84
    Pivot Point 19.86 19.86 19.95 19.89 19.86
    Support 1 (S1) 19.51 19.55 19.69 19.56 19.08
    Support 2 (S2) 19.05 19.36 19.08 19.02
    Support 3 (S3) 18.70 19.05 18.95
    Support 4 (S4) 18.75